Open Access Rheumatology: Research and Reviews Dovepress Optimal Management of Dactylitis in Patients with Psoriatic Arthritis

Psoriatic arthritis (PsA) is an inflammatory arthropathy associated with cutaneous psoriasis, which is currently classified as a seronegative spondyloarthropathy. The presence of cutaneous psoriasis is important for correct and early diagnosis of PsA, because the onset of cutaneous lesions usually precedes the appearance of joint manifestation. Thus, dermatologists are able to detect the condition at its inception. PsA has several unique characteristics such as enthesopathy, dactylitis, and abnormal bone remodeling. In particular, dactylitis occurs on the easily observed sites such as digits, and is thus a significant indicator of PsA. It is important to observe not only the fingers but also the toes, because dactylitis involves both digits of the hands and feet. Recently, new ideas regarding the involvement of the interleukin (IL)-23/Th17 axis have emerged, and the dramatic effects of targeting therapies have highlighted the physiological roles of key cytokines such as tumor necrosis factor-α, IL-17A, and IL-23 in psoriasis. As recent insights are shedding light on the pathogenesis of PsA, understanding of the pathogenesis of dactylitis and enthesitis are also progressing. In this article, current views on the optimal management of dactylitis are discussed.

[1]  H. Koenen,et al.  Cellular sources of IL‐17 in psoriasis: a paradigm shift? , 2014, Experimental dermatology.

[2]  P. Helliwell,et al.  Comprehensive Treatment of Dactylitis in Psoriatic Arthritis , 2014, The Journal of Rheumatology.

[3]  P. Emery,et al.  High-resolution MRI assessment of dactylitis in psoriatic arthritis shows flexor tendon pulley and sheath-related enthesitis , 2014, Annals of the rheumatic diseases.

[4]  L. Coates,et al.  Optimisation of rheumatology indices: dactylitis and enthesitis in psoriatic arthritis. , 2014, Clinical and experimental rheumatology.

[5]  L. Misery,et al.  Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  D. Gladman,et al.  Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor , 2014, Annals of the rheumatic diseases.

[7]  O. FitzGerald,et al.  New developments in our understanding of psoriatic arthritis and their impact on the diagnosis and clinical management of the disease , 2014, Journal of the European Academy of Dermatology and Venereology : JEADV.

[8]  A. Armstrong,et al.  Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis , 2014, Drugs.

[9]  A. Gottlieb,et al.  Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial , 2013, The Lancet.

[10]  D. Gladman,et al.  Dactylitis in Psoriatic Arthritis: Prevalence and Response to Therapy in the Biologic Era , 2013, The Journal of Rheumatology.

[11]  Toshiyuki Yamamoto Angiogenic and Inflammatory Properties of Psoriatic Arthritis , 2013, ISRN dermatology.

[12]  D. M. van der Heijde,et al.  Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial , 2013, Annals of the rheumatic diseases.

[13]  Mahboob Rahman,et al.  Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. , 2012, Arthritis and rheumatism.

[14]  T. Mcclanahan,et al.  IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells , 2012, Nature Medicine.

[15]  C. Ritchlin,et al.  Altered Bone Biology in Psoriatic Arthritis , 2012, Current Rheumatology Reports.

[16]  M. Dougados,et al.  Prevalence and clinical characteristics of dactylitis in spondylarthritis: a descriptive analysis of 275 patients. , 2012, Clinical and Experimental Rheumatology.

[17]  P. Emery,et al.  Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails , 2011, Annals of the rheumatic diseases.

[18]  Toshiyuki Yamamoto Psoriatic arthritis: from a dermatological perspective. , 2011, European journal of dermatology : EJD.

[19]  A. Gottlieb,et al.  Management of psoriatic arthritis from the view of the dermatologist , 2011, Nature Reviews Rheumatology.

[20]  A. Barton,et al.  Psoriatic arthritis – what the dermatologist needs to know , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  K. Reich,et al.  Nail psoriasis in Germany: epidemiology and burden of disease , 2010, The British journal of dermatology.

[22]  P. Gisondi,et al.  The Diagnostic and Therapeutic Challenge of Early Psoriatic Arthritis , 2010, Dermatology.

[23]  R. Snyder Psoriatic Arthritis: A Dermatologist’s Perspective , 2010, American journal of clinical dermatology.

[24]  M. Benjamin,et al.  The pathogenesis of psoriatic arthritis and associated nail disease: not autoimmune after all? , 2009, Current opinion in rheumatology.

[25]  K. Reich,et al.  Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey , 2009, Journal of the European Academy of Dermatology and Venereology : JEADV.

[26]  K. Reich,et al.  Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque‐type psoriasis , 2009, The British journal of dermatology.

[27]  S. Gabriel,et al.  Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. , 2009, Arthritis and rheumatism.

[28]  M. Benjamin,et al.  The Nail as a Musculoskeletal Appendage – Implications for an Improved Understanding of the Link between Psoriasis and Arthritis , 2008, Dermatology.

[29]  I. Olivieri,et al.  Role of Trauma in Psoriatic Arthritis , 2008, The Journal of Rheumatology.

[30]  A. Gottlieb,et al.  Treatment recommendations for psoriatic arthritis , 2008, Annals of the rheumatic diseases.

[31]  D. Aeschlimann,et al.  IL‐23 promotes osteoclast formation by up‐regulation of receptor activator of NF‐κB (RANK) expression in myeloid precursor cells , 2008, European journal of immunology.

[32]  D. Boyle,et al.  The pathobiology of psoriatic synovium , 2008, Current opinion in rheumatology.

[33]  David J J de Gorter,et al.  Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. , 2008, The Journal of bone and joint surgery. American volume.

[34]  N. Kamatani,et al.  IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats , 2007, Arthritis research & therapy.

[35]  A. Silman,et al.  Environmental risk factors for the development of psoriatic arthritis: results from a case–control study , 2007, Annals of the rheumatic diseases.

[36]  M. Benjamin,et al.  The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. , 2007, Arthritis and rheumatism.

[37]  D. Sasseville,et al.  Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. , 2007, Journal of the American Academy of Dermatology.

[38]  I. Olivieri,et al.  Dactylitis or "sausage-shaped" digit. , 2007, The Journal of rheumatology.

[39]  S. Colucci,et al.  Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFα, and IL‐7 in an in vitro model derived from human psoriatic arthritis , 2007, The Journal of pathology.

[40]  Georg Schett,et al.  Dickkopf-1 is a master regulator of joint remodeling , 2007, Nature Medicine.

[41]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[42]  B. Dijkmans,et al.  Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment , 2006, Annals of the rheumatic diseases.

[43]  K. Asadullah,et al.  IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis , 2006, European journal of immunology.

[44]  D. Kane,et al.  Early psoriatic arthritis. , 2005, Rheumatic diseases clinics of North America.

[45]  R. Stern,et al.  Epidemiology of psoriatic arthritis in the population of the United States. , 2005, Journal of the American Academy of Dermatology.

[46]  D. Gladman,et al.  Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[47]  J. Firth,et al.  Development of an assessment tool for dactylitis in patients with psoriatic arthritis. , 2005, The Journal of rheumatology.

[48]  D. Gladman,et al.  Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). , 2005, Arthritis and rheumatism.

[49]  D. Foell,et al.  Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis , 2005, Arthritis research & therapy.

[50]  D. Veale,et al.  Immunopathology of psoriasis and psoriatic arthritis , 2005, Annals of the rheumatic diseases.

[51]  Toshiyuki Yamamoto,et al.  Clinical Analysis of 21 Patients with Psoriasis Arthropathy , 2005, The Journal of dermatology.

[52]  D. Baeten,et al.  Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy , 2005, Arthritis research & therapy.

[53]  Di Chen,et al.  Bone Morphogenetic Proteins , 2004, Growth factors.

[54]  D. Gladman,et al.  Dactylitis in psoriatic arthritis: a marker for disease severity? , 2004, Annals of the rheumatic diseases.

[55]  F. Luyten,et al.  Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA/1 mice: a model of psoriatic arthritis , 2004, Annals of the rheumatic diseases.

[56]  F. Manguso,et al.  Clinical and genetic aspects of psoriatic arthritis "sine psoriasis". , 2003, The Journal of rheumatology.

[57]  L Stafford,et al.  A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. , 2003, Rheumatology.

[58]  E. Schwarz,et al.  Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. , 2003, The Journal of clinical investigation.

[59]  Alexander Fraser,et al.  Angiopoietins, growth factors, and vascular morphology in early arthritis. , 2003, The Journal of rheumatology.

[60]  G. Valesini,et al.  Interleukin 13 in synovial fluid and serum of patients with psoriatic arthritis , 2002, Annals of the rheumatic diseases.

[61]  L. Laloux,et al.  Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis , 2001, Annals of the rheumatic diseases.

[62]  R. Winchester,et al.  Psoriatic Arthritis Joint Fluids Are Characterized by CD8 and CD4 T Cell Clonal Expansions that Appear Antigen Driven1 2 , 2001, The Journal of Immunology.

[63]  D. Reda,et al.  Baseline relationships between psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic arthritis. Department of Veterans Affairs Cooperative Study Group on Seronegative Spondyloarthropathies. , 1999, The Journal of rheumatology.

[64]  P. Emery,et al.  Psoriatic arthritis: a unified concept twenty years on. , 1999, Arthritis and rheumatism.

[65]  B. Bresnihan,et al.  Predominance of CD8+ T lymphocytes in psoriatic arthritis. , 1999, The Journal of rheumatology.

[66]  A. Dunky,et al.  T cell derived cytokines in psoriatic arthritis synovial fluids , 1998, Annals of the rheumatic diseases.

[67]  B. Leeb,et al.  Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. , 1997, The Journal of rheumatology.

[68]  T. Ruzicka Psoriatic arthritis. New types, new treatments. , 1996, Archives of dermatology.

[69]  G Evison,et al.  Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. , 1994, British journal of rheumatology.

[70]  D. Veale,et al.  Classification of clinical subsets in psoriatic arthritis. , 1994, British journal of rheumatology.

[71]  M. Dougados,et al.  The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. , 1991, Arthritis and rheumatism.

[72]  P. Tak,et al.  Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. , 2012, Arthritis and rheumatism.

[73]  M. Genovese,et al.  IL-17 receptor and its functional significance in psoriatic arthritis , 2011, Molecular and Cellular Biochemistry.

[74]  I. Olivieri,et al.  The challenge of early diagnosis of psoriatic arthritis. , 2008, The Journal of rheumatology.

[75]  B. Leeb,et al.  Upregulation of cytokine receptors sTNF-R55, sTNF-R75, and sIL-2R in psoriatic arthritis synovial fluid. , 1998, The Journal of rheumatology.

[76]  H. Shepard,et al.  Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α , 1987, Nature.

[77]  W. Eyler,et al.  PSORIATIC ARTHRITIS. , 1965, Henry Ford Hospital medical bulletin.

[78]  submit your manuscript | www.dovepress.com , 2022 .